Earnings Call · Q4 FY2021·2022-02-17

Q4 21EPS +31.39%·Rev n/aQ3 21EPS +51.92%·Rev n/aQ2 21EPS +19.85%·Rev n/aQ1 21EPS +24.78%·Rev n/a⚠ consensus missing

LIGAND PHARMACEUTICALS INC LGND

Simon Latimer — Investor Relations

John Higgins — Chief Executive Officer

Matt Korenberg — Chief Financial Officer

Matt Foehr — Chief Operating Officer

−8.6%1d on move date−8.0% vs SPY3d−15.3%5d−9.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LGND calls or request research access.

More LGND calls Browse calls Request research access